REFERENCES
1. Gurney JG, Davis S, Severson RK, Fang JY, Ross JA, Robison LL. Trends in cancer incidence among children in the U.S. Cancer 1996 August 1;78(3):532e41.
2. Ladenstein R, Potschger U, Pearson AD, Brock P, Luksch R, Castel V, Yaniv I, Papadakis V, Laureys G, Malis J, Balwierz W, Ruud E, Kogner P, Schroeder H, de Lacerda AF , Beck-Popovic M, Bician P, Garami M, Trahair T, Canete A, Ambros PF, Holmes K, Gaze M, Schreier G, Garaventa A, Vassal G, Michon J, Valteau-Couanet D; SIOP Europe Neuroblastoma Group (SIOPEN).Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncol. 2017;18:500–14.
3. Haupt R, Garaventa A, Gambini C, Parodi S, Cangemi G, Casale F, Viscardi E, Bianchi M, Prete A, Jenkner A, Luksch R, Di Cataldo A, Favre C, D’Angelo P, Zanazzo GA, Arcamone G, Izzi GC, Gigliotti AR, Pastore G, De Bernardi B. Improved survival of children with neuroblastoma between 1979 and 2005: a report of the Italian Neuroblastoma Registry. J ClinOncol. 2010 May 10;28(14):2331-8.
4. K KMatthay, J G Villablanca, R C Seeger, D O Stram, R E Harris, N K Ramsay, P Swift, H Shimada, C T Black, G M Brodeur, R B Gerbing, C P Reynolds. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoicacid. Children’s Cancer Group. N Engl J Med. 1999;341:1165–73.
5. T Philip, R Ladenstein, C Lasset, O Hartmann, J M Zucker, R Pinkerton, A D Pearson, T Klingebiel, A Garaventa, B Kremens, J L Bernard, G Rosti, F Chauvin. 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party. Eur J Cancer. 1997;33:2130–5.
6. A Suc, J Lumbroso, H Rubie, J M Hattchouel, A Boneu, C Rodary, A Robert, O Hartmann. Metastatic neuroblastoma in children older than one year: prognostic significance of the initial metaiodobenzylguanidinescan and proposal for a scoring system. Cancer 1996 February 15;77(4):805-11.
7. Yanik GA, Villablanca JG, Maris JM, Weiss B, Groshen S, Marachelian A, Park JR, Tsao-Wei D, Hawkins R, Shulkin BL, Jackson H, Goodarzian F, Shimada H, Courtier J, Hutchinson R, Haas-Koga D, Hasenauer CB, Czarnecki S, Katzenstein HM, Matthay KK. 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approach to neuroblastoma therapy (NANT) phase II study. Biol Blood Marrow Transplant. 2015 Apr;21(4):673-81.
8. Kraal KC, Bleeker GM, van Eck-Smit BL, van Eijkelenburg NK, Berthold F, van Noesel MM, Caron HN, Tytgat GA. Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients. Eur J Cancer. 2017 May;76:188-196.
9. French S, DuBois SG, Horn B, Granger M, Hawkins R, Pass A, Plummer E, Matthay K. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma. Pediatr Blood Cancer. 2013 May;60(5):879-84.
10. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F.Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993 Aug;11(8):1466-77.
11. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Publish Date: November 27, 2017. Bethesda, MD: National Institutes of Health.
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf
12. Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG, Vogelsang GB, Sensenbrenner LL, Santos GW, SaralR. Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778–783.
13. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Veno-occlusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116–122.
14. Berthold F, Ernst A, Hero B, Klingebiel T, Kremens B, Schilling FH, Simon T. Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation. Br J Cancer. 2018 Aug;119(3):282-290.
15. SIOP EUROPA NEUROBLASTOMA, Protocollo NB-AR-01http://www.chped.it/gico/PRNB.pdf
16. Giammarile F, Chiti A, Lassmann M, Brans B, Flux G; EANM. EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J NuclMedMol Imaging. 2008;35(5):1039‐1047
17. Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, Nakagawara A, Berthold F, Schleiermacher G, Park JR, Valteau-Couanet D, Pearson AD, Cohn SL. Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol. 2015 Sep 20;33(27):3008-17.
18. R J Hutchinson, J C Sisson, J S Miser, K R Zasadny, D P Normolle, B L Shulkin, I R Francis, D M Wieland, B Shapiro. Long-term results of [131I]metaiodobenzylguanidine treatment of refractory advanced neuroblastoma. J Nucl Biol Med. 1991;35:237–240.
19. Voûte PA, Hoefnagel CA, de Kraker J, Valdes Olmos R, Bakker DJ, van de Kleij AJ. Results of treatment with 131 I-metaiodobenzylguanidine in patients with neuroblastoma. Future projects of zetotherapy. ProgClinBiol Res. 1991;366:439–445.
20. Garaventa A, Pianca C, Conte M, Nigro M, De Bernardi B, Claudiani F, Stimamiglio P, Bertolazzi L, Cabria M, Villavecchia GP, et al. Place of meta-[131I]iodobenzylguanidine in the treatment of neuroblastoma: the Genoa experience. Q J Nucl Med. 1995;39:58–60.
21. Miano M, Garaventa A, Pizzitola MR, Piccolo MS, Dallorso S, Villavecchia GP, Bertolazzi C, Cabria M, De Bernardi B. Megatherapy combining I(131) metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma. Bone Marrow Transplant. 2001 Mar;27(6):571-4.
22. Matthay KK, DeSantes K, Hasegawa B, Huberty J, Hattner RS, Ablin A, Reynolds CP, Seeger RC, Weinberg VK, Price D. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J ClinOncol. 1998;16:229–236.
23. Klingebiel T, Bader P, Bares R, Beck J, Hero B, Jürgens H, Lang P, Niethammer D, Rath B, Handgretinger R. Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study. Eur J Cancer. 1998;34:1398–1402.
24. GazeMN, Gains JE, Walker C, Bomanji JB. Optimization of molecular radiotherapy with [131I]-meta Iodobenzylguanidine for high-risk neuroblastoma. Q J Nucl Med Mol Imaging. 2013;57:66–78.
25.Gaze MN, Wheldon TE, O’Donoghue JA, Hilditch TE, McNee SG, Simpson E, Barrett A.Multi-modality megatherapy with [131I]meta-iodobenzylguanidine, high-dose melphalan and total-body irradiation with bone marrow rescue: feasibility study of a new strategy for advanced neuroblastoma. Eur J Cancer. 1995;31A(2):252-6.
26. Matthay KK, Tan JC, Villablanca JG, YanikA, Veatch J, Franc B, Twomey E, Horn B, Reynolds CP, Groshen S, Seeger RC, Maris JM. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approach to Neuroblastoma Therapy Consortium Study. J Clin Oncol. 2006;24:500–506.
27. Lee JW, Lee S, Cho HW, Ma Y, Yoo KH, Sung KW, Koo HH, Cho EJ, Lee SK, Lim DH. Incorporation of high-dose 131I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study. J Hematol Oncol. 2017 May 16;10(1):108.
28. French S, DuBois SG, Horn B, Granger M, Hawkins R, Pass A, Plummer E, Matthay K. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma. Pediatr Blood Cancer. 2013 May;60(5):879-84.
29 . Ferry I, Kolesnikov-Gauthier H, Oudoux A, Cougnenc O, Schleiermacher G, Michon J, Bogart E, Chastagner P, Proust S, Valteau-Couanet D, Defachelles AS. Feasibility of Busulfan Melphalan and Stem Cell Rescue After 131I-MIBG and Topotecan Therapy for Refractory or Relapsed Metastatic Neuroblastoma: The French Experience. J. Pediatr. Hematol Oncol. 2018 Apr 10.
30. Faraci M, Bertaina A, Luksch R, Calore E, Lanino E, Saglio F, Prete A, Menconi M, De Simone G, Tintori V, Cesaro S, Santarone S, Orofino MG, Locatelli F, Zecca M. Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease after Autologous or Allogenic Hematopoietic Stem Cell Transplantation in Children: a retrospective study of the Italian Hematology-Oncology Association-Hematopoietic Stem Cell Transplantation Group. Biol Blood Marrow Transplant. 2019 Feb;25(2):313-320. doi: 10.1016/j.bbmt.2018.09.027. Epub 2018 Sep 26.
31. Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC, Veatch J, Goldsby R, Brophy P, Kersun LS, Hawkins RA, Maris JM. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol2007;25(9):1054–60.
32. Matthay KK, Weiss B, Villablanca JG, Maris JM, Yanik GA, Dubois SG, Stubbs J, Groshen S, Tsao-Wei D, Hawkins R, Jackson H, Goodarzian F, Daldrup-Link H, Panigrahy A, Towbin A, Shimada H, Barrett J, Lafrance N, Babich J. Dose escalation study of no-carrier-added 131 Imetaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to Neuroblastoma Therapy Consortium trial. J NuclMed 2012; 2012:1155–63.
33 . Garaventa A, Bellagamba O, Lo Piccolo MS, Milanaccio C, Lanino E, Bertolazzi L, Villavecchia GP, Cabria M, Scopinaro G, Claudiani F, De Bernardi B. 131 I-metaiodobenzylguanidine (131 IMIBG) therapy for residual neuroblastoma: a mono-institutionalexperience with 43 patients. Br J Cancer 1999;81(8):1378–84
34. Ladenstein R, Pötschger U, Valteau-Couanet D, Luksch R, Castel V, Yaniv I, Laureys G, Brock P, Michon JM, Owens C, Trahair T, Chan GCF, Ruud E, Schroeder H, Beck Popovic M, Schreier G, Loibner H, Ambros P, Holmes K, Castellani MR, Gaze MN, Garaventa A, Pearson ADJ, Lode HN. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018 Dec;19(12):1617-1629.
35. Peinemann F, van Dalen EC, Enk H, Tytgat GA. Anti-GD2 antibody-containing immunotherapy post-consolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation. Cochrane Database Syst Rev. 2019 Apr 24;4:CD012442.